Phenacyl group containing amide derivative of dehydroabietylamine exhibiting enhanced cytotoxic activity against PLC and MCF7 cancer cell lines

Mustufa M. A., Aslam A., Ozen C., Hashmi I. A., Naqvi N. u. H., Ozturk M., ...Daha Fazla

MEDICINAL CHEMISTRY RESEARCH, cilt.26, sa.7, ss.1367-1376, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s00044-017-1859-0
  • Dergi Adı: MEDICINAL CHEMISTRY RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1367-1376
  • Anahtar Kelimeler: Cancer, Dehydroabietylamine, Amides, Cytotoxic activity, NMR spectroscopy, FTIR, CARBOXYLIC-ACIDS, ENDOCANNABINOIDS, ANALOGS, ASSAY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

New amide derivatives of (+)-dehydroabietylamine, tricyclic abietane diterpene amine, were prepared using Zhongping's protocol. (+)-N-(2-phenyl-acetyl)-dehydroabietylamine derivative (11) demonstrated noticeable growth attenuation of hepatocellular carcinoma cell lines including PLC/PRF/5, SNU475, Hep3B-TR, and Huh7 with IC50 of 7.4 A mu M, 9.8 A mu M, 11.7 A mu M, and 11.8 A mu M, respectively. A breast cancer cell line MCF7 was the most sensitive against amide 11 with lowest IC50 value (4.8 A mu M). Low cell confluence and increase in G2/M phase was recorded after 48 and 72 h of treatment of amide 11 on PLC/PRF/5 cell line. Finally, amide 11 has comparatively sufficient therapeutic role due to addition of N-phenacyl group at C-18. Amide 11 demonstrated as potential candidate for future cancer interference and research.